Pharma continues to attract PE investments: Care Ratings
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site
Subscribe To Our Newsletter & Stay Updated